News on qPCR, digital PCR, amplification, point-of-care testing platforms in genetics, genomics, and molecular diagnostics.
The partners will identify patients with gastrointestinal or endometrial cancers who may benefit from immune checkpoint inhibitor therapy using Biotype's technology.
The firm’s test for detecting flu and differentiating between subtypes A and B is being launched in Europe, Asia, and South America.
The company will rely more on distribution partners in Europe for its Unyvero product line while continuing highly targeted commercialization efforts in the US.
The test is a 15-biomarker quantitative PCR panel used to stratify patients with Crohn's disease and ulcerative colitis based on the severity of their illness.
The life science research tools firm is offering 8,150,000 shares of its common stock at a price of $6.75 per share for gross proceeds of about $55 million.
